{"nctId":"NCT05076149","briefTitle":"A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation","startDateStruct":{"date":"2021-10-27","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":597,"armGroups":[{"label":"ELX/TEZ/IVA","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ELX/TEZ/IVA","Drug: IVA","Drug: Placebo (matched to VX-121/TEZ/D-IVA)"]},{"label":"VX-121/TEZ/D-IVA","type":"EXPERIMENTAL","interventionNames":["Drug: VX-121/TEZ/D-IVA","Drug: Placebo (matched to ELX/TEZ/IVA)","Drug: Placebo (matched to IVA)"]}],"interventions":[{"name":"VX-121/TEZ/D-IVA","otherNames":["VX-121/VX-661/CTP-656","VX-121/VX-661/VX-561","VX-121/tezacaftor/deutivacaftor"]},{"name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"name":"IVA","otherNames":["VX-770","ivacaftor"]},{"name":"Placebo (matched to VX-121/TEZ/D-IVA)","otherNames":[]},{"name":"Placebo (matched to ELX/TEZ/IVA)","otherNames":[]},{"name":"Placebo (matched to IVA)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Participant has one of the following genotypes:\n\n  * Homozygous for F508del;\n  * Heterozygous for F508del and a gating (F/G) mutation;\n  * Heterozygous for F508del and a residual function (F/RF) mutation;\n  * At least 1 other TCR CFTR gene mutation identified as responsive to ELX/TEZ/IVA and no F508del mutation\n* Forced expiratory volume in 1 second (FEV1) value \\>=40% and \\<=90% of predicted mean for age, sex, and height for participants currently receiving CFTR protein modulator therapy; FEV1 \\>=40% and \\<=80% for participants not currently receiving CFTR protein modulator therapy\n\nKey Exclusion Criteria:\n\n* History of solid organ or hematological transplantation\n* Hepatic cirrhosis with portal hypertension, moderate hepatic impairment (Child Pugh Score 7 to 9), or severe hepatic impairment (Child Pugh Score 10 to 15)\n* Lung infection with organisms associated with a more rapid decline in pulmonary status\n* Pregnant or breast-feeding females\n\nOther protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change in Percent Predicted Forced Expiratory Volume in 1second (ppFEV1)","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Sweat Chloride (SwCl)","description":"Sweat samples were collected using an approved collection device.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":null},{"groupId":"OG001","value":"-5.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SwCl <60 Millimole Per Liter (mmol/L) (Pooled With Data From Study VX20-121-102)","description":"Sweat samples were collected using an approved collection device.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","spread":null},{"groupId":"OG001","value":"85.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SwCl <30 mmol/L (Pooled With Data From Study VX20-121-102)","description":"Sweat samples were collected using an approved collection device.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","spread":null},{"groupId":"OG001","value":"30.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":40,"n":289},"commonTop":["Infective pulmonary exacerbation of cystic fibrosis","COVID-19","Cough","Nasopharyngitis","Upper respiratory tract infection"]}}}